Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line

Ketkaew, Yuwaporn; Osathanon, Thanaphum; Pavasant, Prasit; Sooampon, Sireerat

doi:10.1016/j.archoralbio.2016.11.010

Cited by 40 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CSCs are closely associated with drug resistance, metastasis and the recurrence of cancer. In the head and neck squamous cell carcinoma cell lines HN-8, HN-30 and HSC-3, apigenin significantly downregulated the stem cell markers of CD44, NANOG, and CD105, and abolished the hypoxia-induced increase in CD44(+) cells, CD105(+) cells and STRO-1(+) cells [ 63 ]. In human glioblastoma cells, apigenin inhibited both the self-renewal capacity, such as cell growth and clonogenicity, and the invasiveness of GBM stem-like cells by blocking the activation of c-Met signaling [ 64 ].…”

Section: Apigenin In Cancer Therapymentioning

confidence: 99%

Apigenin in cancer therapy: anti-cancer effects and mechanisms of action

et al. 2017

View full text Add to dashboard Cite

Apigenin is a common dietary flavonoid that is abundantly present in many fruits, vegetables and Chinese medicinal herbs and serves multiple physiological functions, such as strong anti-inflammatory, antioxidant, antibacterial and antiviral activities and blood pressure reduction. Therefore, apigenin has been used as a traditional medicine for centuries. Recently, apigenin has been widely investigated for its anti-cancer activities and low toxicity. Apigenin was reported to suppress various human cancers in vitro and in vivo by multiple biological effects, such as triggering cell apoptosis and autophagy, inducing cell cycle arrest, suppressing cell migration and invasion, and stimulating an immune response. In this review, we focus on the most recent advances in the anti-cancer effects of apigenin and their underlying mechanisms, and we summarize the signaling pathways modulated by apigenin, including the PI3K/AKT, MAPK/ERK, JAK/STAT, NF-κB and Wnt/β-catenin pathways. We also discuss combinatorial strategies to enhance the anti-cancer effect of apigenin on various cancers and its use as an adjuvant chemotherapeutic agent to overcome cancer drug resistance or to alleviate other adverse effects of chemotherapy. The functions of apigenin against cancer stem cells are also summarized and discussed. These data demonstrate that apigenin is a promising reagent for cancer therapy. Apigenin appears to have the potential to be developed either as a dietary supplement or as an adjuvant chemotherapeutic agent for cancer therapy.

show abstract

Section: Apigenin In Cancer Therapymentioning

confidence: 99%

Apigenin in cancer therapy: anti-cancer effects and mechanisms of action

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Apigenin (4 ,5,7-trihydroxyflavone), one of the most widespread flavonoids in plants has been under tight investigation for its anti-cancer activities and its low toxicity [54]. Api was reported to impact in vitro and in vivo the biology of various human cancers by triggering cell apoptosis [55] and autophagy, inducing cell-cycle arrest [55,56], inhibiting cell migration and invasion [55], stimulating the immune response [57], and suppressing cancer stem cells (CSCs) [58,59]. Api has thus shown broad anticancer effects in various types of cancers, including colorectal, breast, liver, lung, prostate cancers, melanoma and osteosarcoma [55,[60][61][62][63].…”

Section: Discussionmentioning

confidence: 99%

Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors

Leclair

Tardif

Paris

et al. 2020

IJMS

View full text Add to dashboard Cite

: BRAF and MEK inhibitors (BRAFi and MEKi) are the standard of care for the treatment of metastatic melanoma in patients with BRAFV600E mutations, greatly improving progression-free survival. However, the acquisition of resistance to BRAFi and MEKi remains a difficult clinical challenge, with limited therapeutic options available for these patients. Here, we investigated the therapeutic potential of natural flavonoids as specific AhR (Aryl hydrocarbon Receptor) transcription factor antagonists in combination with BRAFi. Experimental Design: Experiments were performed in vitro and in vivo with various human melanoma cell lines (mutated for BRAFV600E) sensitive or resistant to BRAFi. We evaluated the role of various flavonoids on cell sensitivity to BRAFi and their ability to counteract resistance and the invasive phenotype of melanoma. Results: Flavonoids were highly effective in potentiating BRAFi therapy in human melanoma cell lines by increasing sensitivity and delaying the pool of resistant cells that arise during treatment. As AhR antagonists, flavonoids counteracted a gene expression program associated with the acquisition of resistance and phenotype switching that leads to an invasive and EMT-like phenotype. Conclusions: The use of natural flavonoids opens new therapeutic opportunities for the treatment of patients with BRAF-resistant disease.

show abstract

“…Apigenin impairs OSCC cells due to its cytotoxic effects and its ability to act as cell cycle modulator [124]. Further it can inhibit hypoxia-induced stem cell marker expression [125]. Apigenin’s antitumor effects are due to the fact that apigenin regulates all carcinogenesis stages.…”

Section: In Vitro and In Vivo Anti-oral Mucosal Lesions Effectsmentioning

confidence: 99%

Plant-Derived Bioactives in Oral Mucosal Lesions: A Key Emphasis to Curcumin, Lycopene, Chamomile, Aloe vera, Green Tea and Coffee Properties

et al. 2019

View full text Add to dashboard Cite

Oral mucosal lesions have many etiologies, including viral or bacterial infections, local trauma or irritation, systemic disorders, and even excessive alcohol and tobacco consumption. Folk knowledge on medicinal plants and phytochemicals in the treatment of oral mucosal lesions has gained special attention among the scientific community. Thus, this review aims to provide a brief overview on the traditional knowledge of plants in the treatment of oral mucosal lesions. This review was carried out consulting reports between 2008 and 2018 of PubMed (Medline), Web of Science, Embase, Scopus, Cochrane Database, Science Direct, and Google Scholar. The chosen keywords were plant, phytochemical, oral mucosa, leukoplakia, oral lichen planus and oral health. A special emphasis was given to certain plants (e.g., chamomile, Aloe vera, green tea, and coffea) and plant-derived bioactives (e.g., curcumin, lycopene) with anti-oral mucosal lesion activity. Finally, preclinical (in vitro and in vivo) and clinical studies examining both the safety and efficacy of medicinal plants and their derived phytochemicals were also carefully addressed.

show abstract

Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line

Cited by 40 publications

References 38 publications

Apigenin in cancer therapy: anti-cancer effects and mechanisms of action

Apigenin in cancer therapy: anti-cancer effects and mechanisms of action

Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors

Plant-Derived Bioactives in Oral Mucosal Lesions: A Key Emphasis to Curcumin, Lycopene, Chamomile, Aloe vera, Green Tea and Coffee Properties

Contact Info

Product

Resources

About